

# A Summary of the Clinical Considerations for Diagnosis and Reporting of a Patient with COVID-19 mRNA Vaccine Myocarditis/Pericarditis





#### **Presentation**

## Seen with both mRNA vaccines

Commonly seen after second dose, but can occur after the first.

Often seen within the first week post vaccination.

#### Symptoms:

Fever
Chest pain
Dyspnea
Palpitations
Syncope
Diaphoresis



#### **Assessment**

### Diagnostic testing and referral

#### Recommended tests:

Troponin
CRP
COVID-19 PCR
CBC, electrolytes, Cr,
LFTs
ECG

When clinical assessment and lab testing are significant, obtain TTE.

Consider cardiology referral



#### **Case Definition**

#### Various criteria

Brighton criteria CDC criteria

High clinical index of suspicion



#### Reporting

#### **Contacts**

Local Medical Officer

Canadian Adverse
Events following
Immunization
Surveillance System
(CAEFISS)

https://www.canada.ca/ en/public-health/ services/immunization/ canadian-adverseevents-followingimmunizationsurveillance-systemcaefiss.html



CCS.CA

© Canadian Cardiovascular Society 2021 August 2021